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Breast cancer is one of the leading causes of cancer death among women of all races. Pain is a common symptom associated with
cancer; 75–90% of cancer patients experience pain during their illness and up to 50% of that pain is undertreated. Unrelieved pain
leads to increased levels of the stress hormone cortisol. The purpose of this study was to examine the impact of bioenergy on fecal
cortisol levels for mice injected with murine mammary carcinoma 4T1 in two separate pilot studies. Using a multiple experimental
group design, six to eight week old female BALB/c mice were injected with tumor and randomly assigned, in groups of 10, to daily
treatment, every other day treatment, and no treatment groups. Five days after tumor cell injection, bioenergy interventions were
begun for a period of ten consecutive days. Fecal samples were collected for each study and ELISA analysis was conducted at the
end of both studies. For both studies, cortisol levels were decreased in the every other day treatment groups but remained high in
the no treatment groups. Future studies utilizing bioenergy therapies on cortisol levels in a murine breast cancer model can begin
to describe pain outcomes and therapeutic dose.
1. Introduction
Breast cancer is the most common cancer diagnosis for
women in the United States and is one of the leading causes
of cancer death among women of all races. According to the
Center for Disease Control and Prevention, 211,831 women
in the United States were diagnosed with breast cancer in
2009 and 40,676 women in the United States died from that
diagnosis [1]. Pain is a common symptom associated with
cancer; 75–90% of cancer patients experience pain during
their illness and up to 50% of that pain is undertreated [2].
Pain that continues or is unrelieved (up to 50%) significantly
impacts the patient and his/her family, making the diagnosis
of cancer and progression of the disease even more difficult
[2]. Unrelieved pain has been linked to increased levels of
stress, as measured by the stress hormone cortisol [3], and
increased levels of anxiety. Opioids are recognized by the
WHO as the first line of treatment for cancer pain. Opioid
therapies are effective and are relied upon heavily for man-
agement of cancer pain, but these therapies are not without
side effects such as constipation, urinary retention, nausea,
sedation, respiratory depression,myoclonus, delirium, sexual
dysfunction, and hyperalgesia [3].
Complementary and AlternativeMedicine (CAM) thera-
pies are increasingly used by practitioners and patients alike
to manage pain and are without the side effects known to be
associated with opioids. In 1998, surveys on the use of CAM
therapies by cancer patients were reported as high as 64%
and as low as 7% [4]. According to the 2014 report by the
National Cancer Institute at the National Institutes of Health,
more than 50% of cancer patients use some form of CAM
therapy [5]. CAM therapies that are found to be effective for
pain related symptoms without the opioid side effects include
acupuncture, biofield (Reiki, healing touch), massage, cranial
stimulation, music therapy, and foot baths [6]. Acupuncture,
biofield therapies,massage, and cranial stimulation remove or
lessen blockages in pathways or channels that can lead to dis-
ruptions or disturbances in the flow of energy throughout the
body. Once those blockages are removed, balance is restored
to enable the body’s innate tendency for healing to occur.
More recently, psychoeducational interventions, Chinese
herbal medicine, compound kushen injection, reflexology,
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lycopene, TENS, qigong, cupping, cannabis, homeopathy
(Traumeel), and creative arts have also been found to have
some positive impact on cancer pain [7–11]. These therapies
impact the flow of energy as well and promote homeostasis,
balance, and relaxation which is believed to impact pain
and stress in a significant way. An area of special interest
to the National Center for Complementary and Integrative
Medicine (NCCIM) is alleviating pain and inflammation
processes which makes continued research in this area of
particular importance [7].
Women fear breast cancer more than any other disease
and their levels of breast cancer-specific intrusions are related
to their increased stress and perceived risk of breast cancer
[12]. Cortisol is viewed as a physiological marker of stress
[12, 13]. Chronic stress and cortisol deregulation can influence
inflammation and immune function in ways that promote
fatigue, depression, and risk of cancer recurrence [14, 15].
The stress of advancing cancer and management of it is
associated with endocrine and immune dysfunction that
has significant, negative consequences for host resistance to
cancer progression [16].
At least a third of all patients who undergo treatment for
cancer develop psychological morbidity, persisting through-
out the disease continuum from suspicion to diagnosis, treat-
ment, and beyond [17]. Others would say that psychological
symptoms of distress are reported in as many as 41% of
patients with a new diagnosis of breast cancer [18]. In an
earlier study, 49.6% of women with early breast cancer were
clinically anxious and 37.2% were clinically depressed in the
first three months following surgery [19]. Later studies would
show that 48% of women diagnosed with early breast cancer
were clinically anxious and/or depressed in the first year [19].
The impact of anxiety for breast cancer patients has the
potential to impact treatment response, decisionmaking, and
overall quality of life [17, 20, 21]. High levels of stress reactivity
have recently been related to poor compliance with medical
care and low quality of life scores for breast cancer survivors
[22].
Stress-induced immunosuppression associatedwith diag-
nosis and treatment of breast cancer is well established [23].
High levels of stress in cancer patients have also been shown
to negatively impact the immune system leading to elevations
in proinflammatory cytokines and stress hormones. Studies
have also demonstrated a relationship between stress and
decreased immune measurements, even describing a rela-
tionship between the types of stress (acute versus chronic)
involved and decreased function of immune systems [23–
31]. Complementary alternative modalities, in particular
bioenergy therapies, are showing promise in their abilities to
mediate the impact of these dysfunctions.
Biofield modalities are putative in nature, meaning they
are yet to be measured using Western empirical measures.
Practices based on putative energy fields (also called bio-
fields) generally reflect the concept that human beings are
infused with subtle forms of energy. Practitioners are thought
to modulate human biofields by identifying and then remov-
ing energy movement blockages. Some would argue that
because this energy has never been demonstrated beyond
a reasonable doubt, it lacks biological plausibility [32]. How-
ever patients continue to seek out these modalities and more
sophisticated research methods are leading to a body of evi-
dence that would support continued inquiry into the practice
and results of bioenergy.
As reviewed above, stress and increased cortisol can
negatively impact pain, immune function, and influence the
formation and growth of cancers. Because stress hormones
(like cortisol) are known to enhance tumor growth, angio-
genesis, and invasion as well as impair cellular immune re-
sponses, a variety of cancer growth processes may be blunted
and immunity supported by biofield therapies [17, 28, 32–37].
Published reviews regarding the utility of CAM therapies,
to include bioenergy studies, have concluded that more re-
search is needed to demonstrate, more specifically, the effi-
cacy, meaning, and underlying mechanisms influenced by
energy therapies and invited a more expansive view of what
constitutes evidence. These reviews have recommended con-
tinued examination of specific biomarkers associated with
stress and relaxation response systems to assist in deter-
mining the impact of biofield therapies on physiology and
concluded that because of small sample size, high het-
erogeneity across studies, and high risk of bias for primary
studies they could not recommend any CAM interventions
for adult cancer pain.Murinemodels may be onemechanism
that can begin to address some of these issues.
The current study explores the effects of biofield therapies
on cortisol levels in mice injected with breast cancer cells.
Aims of the study are as follows.
(1) To determine whether mice injected with breast can-
cer cells and then treated with bioenergy demonstrate
decreased levels of cortisol.
(2) To determine if the results of the first study could be
replicated with a different bioenergy practitioner.
2. Materials and Methods
2.1. Design. This study used a randomized, two-group
repeatedmeasures design. In two separate studies, two groups
of interventional mice (daily healing touch and every other
day healing touch) were compared to each other and to
a group of untreated mice. Data were collected at two
points: day 3 (before treatment) and day 12 (after treatment)
(Figure 1).
2.2. Samples. For each study, thirty-six- to eight-week-old
BALB/c mice (15–25 g) were obtained from Charles River
Laboratories. The mice were housed in a ventilated barrier
rack in a temperature controlled facility on a 12 h photop-
eriod. The mice were given food and water ad libitum.
This research was conducted under a protocol approved by
the Montana State University, Bozeman Institutional Animal
Care and Use Committee (IACUC).
The 6-thioguanine-resistant 4T1 mouse mammary carci-
noma cell line was obtained from the American Type Cul-
ture Collection (Rockville, MD) and grown in RPMI 1640
medium supplemented with 10% fetal bovine serum and
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(2) McKay bioenergy every other day p (n = 10)
Figure 1: Consort Flow Diagram.
1% each of essential amino acids, L-glutamine, peni-
cillin/streptomycin, and 10mMHEPES. Cells were harvested
for injection with 1X Trypsin/EDTA (Corning) to detach
cells from the flask. Cells were then washed three times with
Dulbecco’s PBS and resuspended in DPBS for injection.
2.3. Procedure. Mice were randomly assigned to cages (five
mice per cage, two cages per group, as per power analysis
and literature review) when they arrived to the Animal
Resource Center (ARC) and remained in those groups for the
duration of the study. Five days after arrival, allowing time
for acclamation to the ARC and their group, each mouse was
injected with 100,000 cells of 4T1 murine mammary breast
cancer tumor subcutaneously in 0.1mL in the lower right
mammary gland (day 1). Five days after injection (day 5),
allowing time for tumor establishment, the intervention for
each group began and continued for ten consecutive days.
Study one employed a certified healing touch practitioner.
Group 1 received bioenergy treatment daily, group 2 received
bioenergy treatment every other day, while group 3 received
no treatment. The literature is not clear on duration of ther-
apeutic treatment time. After consulting with an animal heal-
ing touch practitioner and reviewing the literature, it was
decided to set a treatment time of 10 minutes per group.
Study two employed a bioenergy practitioner trained in
The McKay method. Following the same procedure, group
1 received bioenergy treatment daily and group 2 received
bioenergy treatment every other day, while group 3 received
no treatment. For this study, treatment time lasted 10–20
minutes depending on the practitioner’s daily assessment.
For each study, at the same time every day, the researcher
would gown, enter the roomwhere themice were kept, glove,
turn on the air exchange fan in the biosafety hood, move the
appropriate cages from the rack, and place them under the
hood. For each intervention group, the two cages (five mice
in each cage) were placed side by side under the air exchange
hood. Once the cages were placed under the hood, the plastic
cover of the cage, along with the water which is kept inside
the cage, was moved to the side of the hood leaving the metal
slotted cover over each cage intact providing access to the
mice for the practitioner.The researcher would then leave the
room and the bioenergy practitioner would gown, enter the
room, and prepare for the session (Figure 2).
Each healer prepared for the session by centering and
aligning themselves, attuning to the mice and assessing their
energy fields. The bioenergy practitioners then used a “hand
scan” over the cages to determine levels of energy or auric
field for each group. The practitioner would then “hold the
field” to intensify energy to the mice and use “pain drain”
to drain away irregularity from a specific or general area of
the mouse bodies. “Hands in motion” would then be used to
soothe and calm the field, and “hands still” was used to ener-
gize the spleen and adrenals. At no time did the practitioner
come in physical contact with any of the experimental mice.
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Figure 2: Practitioner setup for bioenergy intervention.
At the end of each treatment the practitioner would
acknowledge the contribution of the mice, remove them-
selves from the mouse energy field, and leave the room. The
researcher would return to the room, replace the water and
plastic cover over each of the mice cages, and place the mice
back in the same spot on the rack.
On day 3 and day 12 (three hours after receiving the bio-
energy treatment) fecal samples were collected from each of
the intervention and control mice. Stool samples were stored
at −80 until analyzed. On day 15 of each study all of the mice
were euthanized following IACUC protocol.
2.4. Extraction and Analysis of Fecal Cortisol. Fecal sam-
ples were weighed and then homogenized in 1mL of 80%
methanol. Sampleswere then shaken for 30minutes on amul-
tivortex. After shaking, samples were centrifuged for 10min
at 2500 g. An aliquot of each supernatant was then diluted
(1 : 5) in assay buffer and analyzed by ELISA (Cortisol EIA
kit, Enzo Life Sciences, Farmingdale, NY) as recommended
by manufacturer.
2.5. Statistical Analyses. Statistical analyses were performed
using Prism 4 (GraphPad Software, San Diego, CA). Fecal
cortisol levels were compared by two-way ANOVA.
3. Results and Discussion
Thegoal of the first study was to determine if cortisol levels in
mice with cancer could be influenced by healing touch. Fecal
cortisol levels of pooled fecal matter from each cage of mice
(2 cages/group) were examined at two time points. The first
was two days after tumor injection and two days before the
first treatment (day 3) and the second was near the end of
the experiment, seven days after treatment began (day 12).
At day 3, the fecal cortisol levels (measured as pg/mL/g)
for the untreated (𝑥 = 167958.2 and SD = 87684.2), every
other day treatment (𝑥 = 169258.9 and SD = 80096.4), and
daily treatment (𝑥 = 134221.5 and SD = 96297.9) groups were
similar (Figure 3(a)). However, at day 12, fecal cortisol levels
appeared to be lower in the every other day (𝑥 = 55784.7
and SD = 13396.8) and daily (𝑥 = 70997.9 and SD = 31523.8)
treatment groups compared to the untreated group (𝑥 =
154480.9 and SD = 9562.4). In addition, fecal cortisol levels
appeared to be reduced between day 3 and day 12 in the every
other day and daily treatment groups, but not the untreated
group. The data was not statistically significant, likely due
to the small number of samples per group, but these data
provided preliminary evidence that cortisol levels in mice
with cancer could be influenced by healing touch.
In study 2, we analyzed the cortisol levels of each mouse
and enhanced our sample numbers (9 or 10 mice/group). We
also wanted to determine if we could get similar results to the
first study with a different practitioner. Before treatment, at
day 3, fecal cortisol levels were higher in the every other day
(𝑥 = 246525.3 and SD = 229323.6) and daily treatment (𝑥 =
151709.3 and SD = 118512.0) groups than the untreated group
(𝑥 = 55104.3 and SD = 61825.2) (Figure 3(b)). This difference
was statistically significant between the untreated and every
other day treatment group. However, after treatment, on day
12, fecal cortisol levels were actually lower in the every other
day (𝑥 = 134028.0 and SD = 86815.5) and daily treatment
(𝑥 = 196557.1 and SD = 122664.4) groups compared to the
untreated group (𝑥=307396.8 and SD=255547.9). Again, this
difference was statistically significant between the untreated
and every other day treatment groups. Furthermore, fecal
cortisol levels significantly increased in the untreated group
between days 3 and 12, but not in the treated groups.
Bioenergy interventions were successful, in two separate
pilot studies with two different practitioners, at reducing the
levels of cortisol in female mice injected with mammary
carcinoma 4T1 compared to untreated mice. These data are
in agreement with what has been observed in clinical studies
[11, 13–15, 20, 25–30]. While the first study results were not
statistically significant, the direction of the relationship was
compelling and the results from the second study further
supported these preliminary findings.
In both studies, the mice receiving bioenergy treatments
every other day had the lowest cortisol levels towards the end
of the experiment. This suggests that there may be a dose
effect to bioenergy interventions, but further studies would
be needed to confirm this. Altogether, these data provide
preliminary evidence that murine models may be a useful
tool for exploration into the efficacy and mechanisms of
action of bioenergy interventions on stress and possibly other
physiological responses. Future studies that build on these
findings are in line with NCCAMs call for the employment of
animal models and methodology in basic and translational
research to study the biological effects and mechanisms of
action underlying CAM approaches [6].
Sample sizes for the two studies, though small, were
typical for murine research and pilot studies. Cortisol levels
are known to be variable, and in murine models there are no
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Figure 3: Fecal cortisol levels measured by ELISA. (a) Study 1 levels for untreated group (𝑛 = 2), every other day treatment group (𝑛 = 2), and
daily treatment group (𝑛 = 2). (b) Study 2 levels for untreated group (𝑛 = 9), every other day treatment group (𝑛 = 10), and daily treatment






indicators available for normal cortisol levels or ranges, so
normal values are not available for comparison.
4. Conclusions
Both of the aims developed for this study were accomplished.
Through this research we were able to prove that mice
injected with breast cancer cells and then treated with bio-
energy demonstrated decreased levels of cortisol.Though the
statistical significance for the first study was not as strong
as the second, in both studies the cortisol levels decreased.
These results would support earlier studies reporting the
effectiveness of bioenergy on cortisol levels, stress, and
immune function.
In regard to the second aim, a second bioenergy practi-
tioner was able to achieve more significant results. As de-
scribed in the methodology section, each practitioner em-
ployed the same techniques, but in the second study the
practitioner was able to extend the time of the intervention.
Because of the need for information on therapeutic dose and
outcomes, the results of this study can be used in future
protocol development.
The provision of complementary alternative modalities
for women with breast cancer must include evidence either
supporting or negating its impact. Incorporating a CAM
modality such as bioenergy, with evidence from rigorous con-
trolled studies, could have far reaching practice implications.
Continued research into dose, length of treatment, and other
variables which could impact efficacy as well as mechanisms
of action is needed to optimize its use in the relief of pain
and the provision of care for cancer patient. These studies
can be difficult to perform in clinical settings. The results
presented here, while limited in scope, provide evidence that
larger scale studies inmurinemodels could be used to address
some of these questions and further examine the impact of
bioenergy interventions in disease models. This knowledge
could then potentially be translated into clinical studies to
provide further evidence for practice. Because cancer pain
will be experienced by asmany as 90%of patients and because
there are no known parameters for therapeutic dose for
many CAM therapies, scientists and practitioners must work
together developing and testing safe interventions to address
this statistic.These pilot studies are a first step in that process.
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